Friday 6 November 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue: −2.20%
EPS: +530.3%
Free cash flow: +16.3%
Total debt: +11.8%

Quarter to September 2026, against a year earlier

313.98 12.31 −3.77%

Follow CRL

Alert me

Market cap: $14.9B
P/E: 300×
Fwd P/E: 89.2×
Dividend yield: —
F-score: 5/9
Altman Z: 2.40
Beneish M: −3.11
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Charles River Laboratories International, Inc. (CRL) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Charles River Laboratories International, Inc. (CRL) trades at a price to free cash flow of 37.6×. Over the past ten years it has ranged from 9.0× (April 2025) to 50.0× (October 2021); the current reading is higher than 90% of that period. That is above the Diagnostics & Research industry median of 33.5× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CRL/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Charles River Laboratories International, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CRL/metrics/price-to-free-cash-flow">Charles River Laboratories International, Inc. (CRL) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	19.1×	0.85%
FY2024	18.9×	(42.43%)
FY2023	32.8×	(12.72%)
FY2022	37.6×	5.65%
FY2021	35.6×	9.33%
FY2020	32.6×	48.99%
FY2019	21.9×	21.32%
FY2018	18.0×	(19.16%)
FY2017	22.3×	62.11%
FY2016	13.8×	(10.38%)

Period	Price to free cash flow	Change
Sep 2026	35.3×	20.08%
Jun 2026	29.4×	36.17%
Mar 2026	21.6×	13.17%
Dec 2025	19.1×	34.64%
43 more quarters	Free account

Against its own ten years

Low 9.0× High 50.0×

Ten-year median 22.1×

Current reading's percentile 90

Company	Price to free cash flow
GH Guardant Health, Inc. compare	n/m
ICLR ICON PLC compare	18.1×
DGX Quest Diagnostics Incorporated compare	20.3×
QGEN QIAGEN N.V. compare	23.8×
LH Labcorp Holdings Inc. compare	25.4×
MEDP Medpace Holdings, Inc. compare	26.6×
RVTY Revvity Inc. compare	28.2×
ILMN Illumina, Inc. compare	30.4×
CRL Charles River Laboratories International, Inc.	37.6×
Diagnostics & Research industry median	33.5×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Charles River Laboratories International, Inc. (CRL) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on CRL

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on CRL

Stockrow Weekly